Lineage Cell Therapeutics Inc LCTX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 1992-03-05 |
| Shares Out. | 249,300,000 |
| Website | lineagecell.com/ ↗ |
| Phone | 15105213390 |
| Employees | 77 |
| Revenue | $1.7M |
| Gross Profit | $1.7M |
| Net Income | -$4.8M |
| Free Cash Flow | -$22.6M |
| Total Assets | $109.5M |
| Total Liabilities | $56.8M |
| Equity | $52.7M |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Lineage Cell Therapeutics Inc is a publicly traded company under the ticker symbol LCTX on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)